Processa Pharmaceuticals Inc PCSA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
Processa Pharmaceuticals Announces Key Leadership Appointments
Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $1.84
- Day Range
- $1.94–1.94
- 52-Week Range
- $1.04–8.88
- Bid/Ask
- $1.30 / $1.95
- Shares Outstanding
- 2.80M
- Market Cap
- $5.14M
- Volume/Avg
- 270 / 84,464
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 12
Valuation
Metric | PCSA |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
PCSA
Financial Strength
Metric | PCSA |
|---|---|
Quick Ratio | 0.28 |
Current Ratio | 0.87 |
Interest Coverage | — |
Quick Ratio
PCSA
Profitability
Metric | PCSA |
|---|---|
Return on Assets (Normalized) | −212.52% |
Return on Equity (Normalized) | −324.78% |
Return on Invested Capital (Normalized) | −326.88% |
Return on Assets
PCSA
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|@?J$CX | LOCK|N#Z% | $138B | |||
| Moderna Inc MRNA | LOCK|mkQQLg | LOCK|M>@ | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|WVny#< | LOCK|@QZ?J | $93B | |||
| argenx SE ADR ARGX | LOCK|Qxn!$s | LOCK|m$ | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|&Jqj^fy | LOCK|vpv | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|<V&@Nv$$ | LOCK|HbzM# | $30B | |||
| Incyte Corp INCY | LOCK|%<NBXH | LOCK|xs | $24B | |||
| BioNTech SE ADR BNTX | LOCK|z%pQy<N | LOCK|$R^ | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|?Jf$D@ | LOCK|RMy! | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|X$??>^ | LOCK|gZV | $15B |
United States